Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Susceptibility of Imipenem-Susceptible but Meropenem-Resistant blaIMP-6-Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol

Sachi Kanazawa, Takafumi Sato, Naoki Kohira, Tsukasa Ito-Horiyama, Masakatsu Tsuji, Yoshinori Yamano
Sachi Kanazawa
Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takafumi Sato
Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoki Kohira
Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsukasa Ito-Horiyama
Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masakatsu Tsuji
Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshinori Yamano
Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00576-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

LETTER

Carbapenemase-producing Enterobacteriaceae (CPE) have been spreading worldwide and are a great concern among health care settings (1). Intriguingly, IMP-6 (encoded by the blaIMP-6 gene), one of the IMP-type metallo-carbapenemases, has been reported to confer the paradoxical imipenem-susceptible but meropenem-resistant (ISMR) phenotype to Enterobacteriaceae strains, and strains carrying blaIMP-6 have recently been isolated throughout Japan (2, 3). This phenotype might lead to misdiagnosis of CPE infections when imipenem is used for antimicrobial susceptibility testing, resulting in inappropriate antimicrobial use and failure to prevent nosocomial transmissions caused by this pathogen. The blaIMP-6 gene differs from the blaIMP-1 gene by one point mutation: adenine at nucleotide 640 in blaIMP-1 is replaced by guanine, corresponding to the amino acid substitution of glycine for serine (4). Although IMP-6 has weaker hydrolysis activity to imipenem as well as some kinds of β-lactams, such as benzylpenicillin and ceftazidime, than IMP-1 (5), CPE-carrying blaIMP-6 shows resistance to almost all the β-lactams except for imipenem, due to the concomitant production of CTX-M-2, an extended-spectrum β-lactamase (ESBL) (2, 3). Here, we investigated the antimicrobial activity of various antibacterials, including compounds recently marketed or currently under development, against the problematic ISMR strains carrying blaIMP-6.

Eighty-two ISMR phenotype Enterobacteriaceae strains (29 Escherichia coli, 22 Klebsiella pneumoniae, 20 Klebsiella oxytoca, 9 Enterobacter cloacae, and 2 Citrobacter freundii strains) isolated in a tertiary hospital in Japan from 2010 to 2014 were used. The existence of blaIMP-6 (guanine at nucleotide position 640) was confirmed by allele-specific PCR in all test strains (4), and blaCTX-M-2-group was detected by PCR in 80 of 82 strains (6). MIC was determined by the CLSI broth microdilution method (7), and the ISMR phenotype was defined as an imipenem MIC of ≤1 mg/liter and a meropenem MIC of ≥4 mg/liter (8). The MIC medium, iron-depleted cation-adjusted Mueller-Hinton broth prepared by treatment with Chelex (Bio-Rad, Hercules, CA), was used for cefiderocol (siderophore cephalosporin) (9).

The MIC90s of cefepime, ceftolozane-tazobactam, ceftazidime-avibactam, and ciprofloxacin were ≥32 mg/liter, while the MIC90s of colistin and amikacin were 0.5 and 8 mg/liter, respectively (Table 1). The two strains with resistance to colistin were K. pneumoniae and E. cloacae strains (MIC data by species are shown in the supplemental file). Recently marketed β-lactam–β-lactamase inhibitor combinations such as ceftolozane-tazobactam and ceftazidime-avibactam have been reported to be active against ESBL producers but inactive against metallo-β-lactamase producers (1, 10), and the results of the present study were consistent with those reports, although the IMP-6 enzyme has remarkable substrate specificity changes. However, the antibacterials in the compound under development, cefiderocol and aztreonam-avibactam, showed MIC90s of 1 and 0.25 mg/liter, respectively, against these ISMR strains, and there were no strains for which the MICs were ≥4 mg/liter. The reports that cefiderocol and aztreonam have quite low kcat/Km or relative Vmax/Km values for IMP-1 suggest that one reason for the good antimicrobial activities of both compounds is the low level of hydrolysis by IMP-6 as well as IMP-1 (5, 11, 12). Although colistin and amikacin showed potent activity against ISMR Enterobacteriaceae in this study, safety issues such as nephrotoxicity remain concerns in clinical settings (13, 14). Alternative treatment options for CPE infections, including those caused by IMP-6-producing strains, are needed.

View this table:
  • View inline
  • View popup
TABLE 1

Susceptibility distribution of 82 imipenem-susceptible but meropenem-resistant Enterobacteriaceae strains carrying blaIMP-6

ACKNOWLEDGMENTS

MIC data collection was supported by T. Hori and Y. Jinushi, Shionogi TechnoAdvance Research Co., Ltd.

We thank A. Naito and T. Yamaguchi for useful advice.

All authors are employees of Shionogi & Co., Ltd., and we have no conflicts of interest to declare.

FOOTNOTES

    • Accepted manuscript posted online 24 April 2017.
  • Supplemental material for this article may be found at https://doi.org/10.1128/AAC.00576-17 .

  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Doi Y,
    2. Paterson DL
    . 2015. Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit Care Med36:74–84. doi:10.1055/s-0035-1544208.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Ohno Y,
    2. Nakamura A,
    3. Hashimoto E,
    4. Matsutani H,
    5. Abe N,
    6. Fukuda S,
    7. Hisashi K,
    8. Komatsu M,
    9. Nakamura F
    . 2017. Molecular epidemiology of carbapenemase-producing Enterobacteriaceae in a primary care hospital in Japan, 2010-2013. J Infect Chemother23:224–229. doi:10.1016/j.jiac.2016.12.013.
    OpenUrlCrossRef
  3. 3.↵
    1. Shigemoto N,
    2. Kuwahara R,
    3. Kayama S,
    4. Shimizu W,
    5. Onodera M,
    6. Yokozaki M,
    7. Hisatsune J,
    8. Kato F,
    9. Ohge H,
    10. Sugai M
    . 2012. Emergence in Japan of an imipenem-susceptible, meropenem-resistant Klebsiella pneumoniae carrying blaIMP-6. Diagn Microbiol Infect Dis72:109–112. doi:10.1016/j.diagmicrobio.2011.09.019.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kayama S,
    2. Shigemoto N,
    3. Kuwahara R,
    4. Onodera M,
    5. Yokozaki M,
    6. Ohge H,
    7. Kato F,
    8. Hisatsune J,
    9. Sugai M
    . 2012. Rapid detection of blaIMP-6 by amplification refractory mutation system. J Microbiol Methods88:182–184. doi:10.1016/j.mimet.2011.10.022.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Liu EM,
    2. Pegg KM,
    3. Oelschlaeger P
    . 2012. The sequence-activity relationship between metallo-β-lactamases IMP-1, IMP-6, and IMP-25 suggests an evolutionary adaptation to meropenem exposure. Antimicrob Agents Chemother56:6403–6406. doi:10.1128/AAC.01440-12.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Sato T,
    2. Hara T,
    3. Horiyama T,
    4. Kanazawa S,
    5. Yamaguchi T,
    6. Maki H
    . 2015. Mechanism of resistance and antibacterial susceptibility in ESBL-phenotype Klebsiella pneumoniae and Klebsiella oxytoca isolated between 2000 and 2010 in Japan. J Med Microbiol64:538–543. doi:10.1099/jmm.0.000057.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
  8. 8.↵
    Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing, 26th ed. CLSI supplement M100S. Clinical and Laboratory Standards Institute, Wayne, PA.
  9. 9.↵
    1. Ito A,
    2. Nishikawa T,
    3. Matsumoto S,
    4. Yoshizawa H,
    5. Sato T,
    6. Nakamura R,
    7. Tsuji M,
    8. Yamano Y
    . 2016. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother60:7396–7401. doi:10.1128/AAC.01405-16.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Vasoo S,
    2. Cunningham SA,
    3. Cole NC,
    4. Kohner PC,
    5. Menon SR,
    6. Krause KM,
    7. Harris KA,
    8. De PP,
    9. Koh TH,
    10. Patel R
    . 2015. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother59:7842–7846. doi:10.1128/AAC.02019-15.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Osano E,
    2. Arakawa Y,
    3. Wacharotayankun R,
    4. Ohta M,
    5. Horii T,
    6. Ito H,
    7. Yoshimura F,
    8. Kato N
    . 1994. Molecular characterization of an enterobacterial metallo β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob Agents Chemother38:71–78. doi:10.1128/AAC.38.1.71.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Ito-Horiyama T,
    2. Ishii Y,
    3. Ito A,
    4. Sato T,
    5. Nakamura R,
    6. Fukuhara N,
    7. Tsuji M,
    8. Yamano Y,
    9. Yamaguchi K,
    10. Tateda K
    . 2016. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother60:4384–4386. doi:10.1128/AAC.03098-15.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Kelesidis T,
    2. Falagas ME
    . 2015. The safety of polymyxin antibiotics. Expert Opin Drug Saf14:1687–1701. doi:10.1517/14740338.2015.1088520.
    OpenUrlCrossRef
  14. 14.↵
    1. Boyer A,
    2. Gruson D,
    3. Bouchet S,
    4. Clouzeau B,
    5. Hoang-Nam B,
    6. Vargas F,
    7. Gilles H,
    8. Molimard M,
    9. Rogues A,
    10. Moore N
    . 2013. Aminoglycosides in septic shock. Drug Saf36:217–230. doi:10.1007/s40264-013-0031-0.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Susceptibility of Imipenem-Susceptible but Meropenem-Resistant blaIMP-6-Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol
Sachi Kanazawa, Takafumi Sato, Naoki Kohira, Tsukasa Ito-Horiyama, Masakatsu Tsuji, Yoshinori Yamano
Antimicrobial Agents and Chemotherapy Jun 2017, 61 (7) e00576-17; DOI: 10.1128/AAC.00576-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Susceptibility of Imipenem-Susceptible but Meropenem-Resistant blaIMP-6-Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Susceptibility of Imipenem-Susceptible but Meropenem-Resistant blaIMP-6-Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol
Sachi Kanazawa, Takafumi Sato, Naoki Kohira, Tsukasa Ito-Horiyama, Masakatsu Tsuji, Yoshinori Yamano
Antimicrobial Agents and Chemotherapy Jun 2017, 61 (7) e00576-17; DOI: 10.1128/AAC.00576-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Drug Resistance, Bacterial
Enterobacteriaceae
Enterobacteriaceae Infections
Genes, Bacterial
imipenem
meropenem
beta-lactamases
CPE
cefiderocol
IMP-6
ISMR

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596